Endovastec(SH:688016) Sou Hu Cai Jing·2026-01-19 11:11Core Viewpoint - The stock of Xinmai Medical (688016) has shown a decline in price and mixed capital flow, indicating potential volatility in investor sentiment and market performance [1][2]. Group 1: Stock Performance - As of January 19, 2026, Xinmai Medical closed at 96.73 yuan, down 1.28% with a turnover rate of 1.17% and a trading volume of 14,500 hands, resulting in a transaction amount of 141 million yuan [1]. - Over the past five days, the stock has experienced a downward trend, with a total decline of 2.61% in main capital flow and a net outflow of 367.48 million yuan on January 19 [2]. Group 2: Financial Metrics and Industry Comparison - Xinmai Medical's total market capitalization is 11.923 billion yuan, slightly above the industry average of 11.393 billion yuan, ranking 30th out of 127 companies in the medical device sector [3]. - The company reported a net profit of 429 million yuan, significantly higher than the industry average of 208 million yuan, ranking 16th in the industry [3]. - The gross profit margin for Xinmai Medical stands at 70.4%, well above the industry average of 50.77%, indicating strong profitability [3]. Group 3: Recent Financial Performance - For the first three quarters of 2025, Xinmai Medical's main revenue reached 1.015 billion yuan, a year-on-year increase of 4.66%, while the net profit decreased by 22.46% to 429 million yuan [3]. - In Q3 2025, the company achieved a quarterly revenue of 300 million yuan, reflecting a substantial year-on-year increase of 64.68%, although the net profit for the quarter decreased by 23.63% [3]. Group 4: Analyst Ratings - In the last 90 days, eight institutions have provided ratings for Xinmai Medical, with seven recommending a buy and one suggesting an increase, indicating a generally positive outlook [4]. - The average target price set by institutions over the past 90 days is 136.03 yuan, suggesting potential upside from the current trading price [4].